Related Experiment Videos
Effect of RA233 on metastasis in dogs with osteosarcomas
H B Hamilton1, S M LaRue, S J Withrow
1Comparative Oncology Unit, Veterinary Teaching Hospital, Colorado State University, Fort Collins 80523.
Abstract:
The influence of RA233, an inhibitor of platelet function, on the occurrence of metastasis in 18 dogs with osteosarcomas was evaluated. At least 24 hours before surgical removal of the primary tumor, dogs were given RA233 orally (20 mg/kg of body weight divided into 3 equal doses). Original sites of the osteosarcoma included humerus, 6 dogs; radius, 5 dogs; tibia, 3 dogs; femur, 2 dogs; maxilla, 1 dog; and mandible, 1 dog. Survival time for 13 dogs euthanatized for progression of neoplastic disease ranged from 3 months to 10 months, with a mean survival time of 5.5 months. Medication was discontinued in 1 dog because of possible adverse reaction. One dog died of disease unrelated to the tumor, and one dog was euthanatized after the surgery. Two dogs were tumor free 9 and 17 months after surgery. Seemingly, the metastasis potential was not diminished in dogs given 20 mg of RA233/kg/day.
Insights
RA233, a platelet function inhibitor, did not reduce metastasis in dogs with osteosarcoma. This study found no significant decrease in the metastasis potential of osteosarcoma in dogs treated with RA233.
Area of Science:
- Veterinary Oncology
- Pharmacology
Background:
- Osteosarcoma is a common bone cancer in dogs, often associated with metastasis.
- Platelet function inhibitors are being investigated for their potential to reduce cancer metastasis.
Purpose of the Study:
- To evaluate the effect of RA233, a platelet function inhibitor, on the occurrence of metastasis in dogs with osteosarcoma.
Main Methods:
- 18 dogs with osteosarcoma received oral RA233 (20 mg/kg/day) starting at least 24 hours before primary tumor surgical removal.
- Tumor sites included humerus, radius, tibia, femur, maxilla, and mandible.
Main Results:
- Survival time for 13 dogs euthanatized due to cancer progression ranged from 3 to 10 months (mean 5.5 months).
- One dog experienced an adverse reaction, one died from unrelated disease, and one was euthanatized post-surgery.
- Two dogs remained tumor-free at 9 and 17 months post-surgery.
Conclusions:
- RA233 administration at 20 mg/kg/day did not appear to diminish the metastasis potential in dogs with osteosarcoma.